BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
BioAge Labs announced positive Phase 1 clinical trial results for BGE-102, a novel oral NLRP3 inhibitor targeting inflammation related to aging and cardiovascular risk. The drug demonstrated significant reductions in hsCRP and other inflammatory biomarkers in obese participants, with good tolerability. Based on these results, BioAge plans to initia…